PMID- 2162506
OWN - NLM
STAT- MEDLINE
DCOM- 19900726
LR  - 20190510
IS  - 0931-0509 (Print)
IS  - 0931-0509 (Linking)
VI  - 5
IP  - 2
DP  - 1990
TI  - A low-molecular-weight heparin (Kabi 2165, 'Fragmin') in repeated use for 
      haemodialysis: prevention of clotting and prolongation of the venous compression 
      time in comparison with commercial unfractionated heparin.
PG  - 135-40
AB  - We have compared a low-molecular-weight heparin (LMWH), Kabi 2165, with 
      commercial unfractionated heparin (UFH) in 21 patients undergoing haemodialysis 
      (1 month with each heparin). The UFH dose regimen comprised a UFH-saline prime of 
      the extracorporeal circuit, an initial bolus of 5000 international units (IU) and 
      an infusion of 1500 IU/h. The LMWH dose regimen comprised a LMWH-saline prime, a 
      bolus of 3000-4000 anti-factor Xa units (aXa U) and an infusion of 750 aXa U/h. 
      Plasma concentrations of the LMWH were slightly less than those of UFH for the 
      first hour of dialysis (0.87 aXa U/ml vs 0.99 IU/ml) but were very similar by the 
      end of the infusion (0.96 vs 1.00) and slightly greater at the end of dialysis, 
      an hour later (0.85 vs 0.69). All haemodialysis sessions were completed 
      uneventfully, with infrequent wispy clot deposits in the drip chamber. The mean 
      frequency of clot deposition was slightly higher with the LMWH (0.20 vs 0.15). 
      Fibrin generation was almost fully suppressed: plasma concentrations of 
      fibrinopeptide A were slightly greater during dialysis with the LMWH (3.31-3.98 
      vs 2.29-2.75 pmol/ml) but were almost identical by the end of dialysis (5.62 vs 
      5.49 pmol/ml). The mean 'venous' compression time at the end of dialysis was 
      significantly shorter with the LMWH than with UFH (8.45 min vs 11.12 min). We 
      conclude that the LMWH is effective and safe in repeated use for haemodialysis. 
      It prevents fibrin generation and clot formation to a similar degree as UFH. The 
      shorter venous compression time of the LMWH may reflect a reduced haemorrhagic 
      risk.
FAU - Anastassiades, E
AU  - Anastassiades E
AD  - Department of Nephrology, Charing Cross Hospital, London.
FAU - Ireland, H
AU  - Ireland H
FAU - Flynn, A
AU  - Flynn A
FAU - Lane, D A
AU  - Lane DA
FAU - Curtis, J R
AU  - Curtis JR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Nephrol Dial Transplant
JT  - Nephrology, dialysis, transplantation : official publication of the European 
      Dialysis and Transplant Association - European Renal Association
JID - 8706402
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Bleeding Time
MH  - Blood Coagulation/*drug effects
MH  - Drug Administration Schedule
MH  - Heparin/*pharmacology
MH  - Heparin, Low-Molecular-Weight/*pharmacology
MH  - Humans
MH  - Pressure
MH  - Renal Dialysis/*methods
MH  - Veins
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1093/ndt/5.2.135 [doi]
PST - ppublish
SO  - Nephrol Dial Transplant. 1990;5(2):135-40. doi: 10.1093/ndt/5.2.135.